• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

CRISPR-Based HIV Gene Therapy Administered To First Human Patient

September 22, 2022 by Deborah Bloomfield

In a clinical trial, the first patient has received a single dose of a new human immunodeficiency virus (HIV) gene editing therapy, researchers at the Lewis Katz School of Medicine at Temple University and Excision BioTherapeutics, Inc have reported.

In a collaborative effort, the researchers are currently running a phase 1/2 clinical trial to evaluate the safety and efficacy of their therapy, called EBT-101, which is based on gene editing technology known as CRISPR. 

Advertisement

“Nearly 40 million people worldwide suffer from the effects of HIV, and more than 40 years after the discovery of HIV/AIDS, there still are no curative treatments,” said Professor Kamel Khalili, who helped lead the trial, in a statement. 

“EBT-101 can potentially address long-standing unmet needs of individuals living with HIV/AIDS by removing viral DNA from their cells, thereby eradicating infection.”

When HIV infects, it takes long-term hold and hides from the immune system in cells, compromising the patient’s immunity over time and eventually leading to the development of AIDS – the progressive failure of a patient’s immune system. There is currently no cure for HIV, but various treatments and medications can help manage the infection and slow or prevent the progression of the disease.

Advertisement



The therapy currently being trialed, which uses CRISPR gene editing to remove HIV viral DNA from infected cells, is a major step toward finding a therapeutic cure.

“We are well-positioned to collect key data that will enable our efforts to translate the success this approach has shown in animal models to human clinical trial participants,” Khalili added. “We look forward to investigating this hypothesis through the EBT-101 clinical program and are pleased that the EBT-101 Phase 1/2 trial is proceeding as planned.”

The first patient to receive a single dose of EBT-101 in the current trial is currently under medical supervision and will soon be assessed to see if there is any viral rebound and whether the single curative treatment worked as planned. This will be a deciding factor in whether or not the patient is able to stop their current antiretroviral therapy in the future.

Advertisement

“The official start of the Phase 1/2 clinical trials for EBT-101 brings us one extremely significant step closer to creating a potential cure for HIV/AIDS,” said Dr Amy J. Goldberg, Interim Dean of the Katz School of Medicine. “This amazing milestone speaks to the exceptional research acumen and scientific knowledge of Drs. Khalili and Burdo and their teams – outstanding members of the Temple family.”

For further details, you can view the clinical trial information at ClinicalTrials and follow its progress.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. ‘Hadestown’ marks return of Broadway musicals after 18-month shutdown
  2. Macron says French forces killed Islamic State leader in Sahara
  3. Italy’s Draghi to meet Greta Thunberg at Milan climate talks – source
  4. How “Diamond Dust” Sparkles In The Sky In Sub-Zero Temperatures

Source Link: CRISPR-Based HIV Gene Therapy Administered To First Human Patient

Filed Under: News

Primary Sidebar

  • “Something Unknown Is At Work Here”: Unexpected Results From NASA Mission To Deflect Asteroid
  • Dangerous Radiation Awaits Astronauts On Mars – New Mission Could Work Out Just How Much
  • A 4.9 Million-Year-Old Ecosystem Of Interconnected Worlds Is Preserved In A Tennessee Sinkhole
  • 100 Years Since The Scopes (Monkey) Trial: How Much Has Changed Since America’s “Trial Of The Century”?
  • Elephants Use All Kinds Of Gestures To Communicate – They Just Want Apples
  • NASA’s Parker Solar Probe Finds Evidence Of “Barrier” In The Sun’s 2 Million Kelvin Atmosphere
  • Watching Videos At Higher Speeds May Save Time But It Has Some Drawbacks
  • In 2008, Ukraine’s Space Agency Sent A Message To Planet Gliese 581c. It Will Arrive In 2029
  • In A First, A Robot Listened To Spoken Instructions And Performed Surgery – Just Like A Human Would
  • Newly Discovered “Bone-Digesting” Cells Help Burmese Pythons Consume Every Last Bit Of Their Prey
  • Gold Can Be Made By Scientists In A Lab – There’s Just One Problem
  • Recovery Of 24-Million-Year-Old Protein Fragments From Extinct Animal Opens “New Chapter” Of Biology
  • 6 Leading Medical Organizations Team Up To Sue RFK Jr Over COVID-19 Vaccine Policy
  • Less Ice, More Fire: Evidence Melting Glaciers Make Volcanic Eruptions More Explosive
  • This Mini Fridge-Sized Spacecraft Could Study A Time Of The Universe We’ve Never Seen Before
  • Psilocybin Shows Potential In Slowing Human Cell Aging And Increasing Lifespan In Mice
  • Blue Sharks’ Freaky Tooth-Skin Makes It Possible For Them To Change Color To Green And Even Gold
  • Summer In The Northern Hemisphere Will Be 15 Minutes Shorter Than Last Year’s
  • Your Ability To Be Funny May Not Be Inherited After All, And That’s Really Unexpected
  • New Interstellar Comet Tracked To Its Origin Region: “It’s Much Older Than The Solar System”
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version